Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/s-0035-1558054 http://scihub22266oqcxt.onion/10.1055/s-0035-1558054 C4629994!4629994 !26556906     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26556906 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Geburtshilfe+Frauenheilkd 2015 ; 75 (10 ): 1043-1050 Nephropedia Template TP {{tp|p=26556906 |t=2015. Gestational Trophoblastic Disorders: An Update in 2015 |pdf=|usr=}}{{26556906 }} gab.com Text Gestational Trophoblastic Disorders: An Update in 2015 JO: Geburtshilfe Frauenheilkd http://www.kidney.de/pget.php?&tw=1&pmid=26556906 #FOAvip Gestational trophoblastic diseases (GTD) are a group of pregnancy-related disorders representing rare human tumours. They encompass premalignant disorders including complete (CHM), partial hydatidiform mole (PHM), exaggerated placental site (EPS), and placental-site nodule (PSN) as well as malignant disorders (also known as "gestational trophoblastic neoplasia [GTN]") including invasive mole, choriocarcinoma (CC), placenta-site trophoblastic tumour (PSTT), and epitheloid trophoblastic tumours (ETT) (Fig.?1). Originally, GTD develop from abnormal proliferation of trophoblastic tissue and form botryoid arranged vesicles. Premalignant moles are usually treated by suction curettage while persistent and recurrent moles and malignant forms require systemic therapy with methotrexate or combination chemotherapy consisting of etoposide, actimomycin D, methotrexate, vincristine, and cyclophosphamide (EMA-CO). ?-human chorion gonadotropin (?-hCG) plays a crucial role in diagnosis and monitoring therapeutic effects. Since the definitive diagnosis cannot be obtained by histology in most cases, persistent or recurrent disease is diagnosed by elevated or persistent serum levels of ?-hCG. While curing rates are described to be as high as 98?%, GTD may initially present, recur, or end up as a metastasising systemic disease. This underlines the importance of a regular and consistent follow-up after treatment. Twit Text FOAVip Gestational Trophoblastic Disorders: An Update in 2015 ????Geburtshilfe Frauenheilkd http://www.kidney.de/pget.php?&tw=1&pmid=26556906 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26556906 #FOAvip English Wikipedia <ref>{{Cite pmid|26556906 }}</ref> Gestational Trophoblastic Disorders: An Update in 2015 #MMPMID26556906 Stevens FT ; Katzorke N ; Tempfer C ; Kreimer U ; Bizjak GI ; Fleisch MC ; Fehm TN Geburtshilfe Frauenheilkd 2015[Oct]; 75 (10 ): 1043-1050 PMID26556906 show ga Gestational trophoblastic diseases (GTD) are a group of pregnancy-related disorders representing rare human tumours. They encompass premalignant disorders including complete (CHM), partial hydatidiform mole (PHM), exaggerated placental site (EPS), and placental-site nodule (PSN) as well as malignant disorders (also known as "gestational trophoblastic neoplasia [GTN]") including invasive mole, choriocarcinoma (CC), placenta-site trophoblastic tumour (PSTT), and epitheloid trophoblastic tumours (ETT) (Fig.?1). Originally, GTD develop from abnormal proliferation of trophoblastic tissue and form botryoid arranged vesicles. Premalignant moles are usually treated by suction curettage while persistent and recurrent moles and malignant forms require systemic therapy with methotrexate or combination chemotherapy consisting of etoposide, actimomycin D, methotrexate, vincristine, and cyclophosphamide (EMA-CO). ?-human chorion gonadotropin (?-hCG) plays a crucial role in diagnosis and monitoring therapeutic effects. Since the definitive diagnosis cannot be obtained by histology in most cases, persistent or recurrent disease is diagnosed by elevated or persistent serum levels of ?-hCG. While curing rates are described to be as high as 98?%, GTD may initially present, recur, or end up as a metastasising systemic disease. This underlines the importance of a regular and consistent follow-up after treatment. äGestational Trophoblastic Disorders: An Update in 2015 (epmc).pdf DeepDyve Pubget Overpricing